Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.48 |
| ▸ | IGF1R | P08069 | 2/20 | 0.44 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.39 |
| ▸ | STK17B | O94768 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | IDH1 | O75874 | 4/20 | 0.38 |
| ▸ | ULK1 | O75385 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3447878 | 0.82 | EGFR (0.48) | EGFRIGF1RSTK17ASTK17BSYK | |
| SCHEMBL3447036 | 0.81 | ULK1 (0.56) | STK17ASTK17BULK1CHEK1FLT3 | |
| SCHEMBL3373633 | 0.81 | ULK1 (0.44) | EGFRSTK17ASTK17BIDH1ULK1 | |
| SCHEMBL3448088 | 0.81 | TBK1 (0.44) | SYKIDH1 | |
| SCHEMBL3373080 | 0.80 | NPC1 (0.46) | IGF1RSYKIDH1FLT3JAK2 | |
| SCHEMBL3373625 | 0.80 | MAPT (0.48) | IGF1RSYK | |
| SCHEMBL3448902 | 0.80 | AURKA (0.46) | SYKIDH1PTK2 | |
| SCHEMBL3449926 | 0.79 | SYK (0.38) | SYKULK1 | |
| SCHEMBL3374211 | 0.78 | IGF1R (0.44) | IGF1RSYKIDH1 | |
| SCHEMBL3450149 | 0.77 | SYK (0.50) | EGFRIGF1RSYKIDH1PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | EGFR 2771/4885IGF1R 4845/4885STK17A 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.